ERBB2 and neoplasm: According to the manufacturer, in vitro experiments that applied the Vizimpro® treatment on human tumors implanted in mice showed that the drug is capable of inhibiting the autophosphorylation of EGFR as well as the human epidermal growth factor receptor 2 (HER2) and limiting the growth of the tumor.